A blood test cannot predict how long you will live.

That is an important distinction.

Long-term health is influenced by genetics, blood pressure, smoking, body composition, physical activity, sleep, diet, socioeconomic factors, existing medical conditions and many other variables.

Blood testing gives us one part of that picture.

What it can do well is measure established markers related to cardiovascular health, glucose regulation, kidney and liver function, blood health, nutritional status and inflammation.

What is actually worth measuring?

No single biomarker gives a complete assessment of long-term health. IMULAB looks across several systems and interprets them together.

Lipids matter, but they need context.

Cardiovascular disease develops over many years, which makes cardiovascular risk one of the more useful areas to understand before there is an obvious problem.

A lipid profile can include total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides and calculated measures such as non-HDL cholesterol. More detailed cardiovascular testing may include additional markers.

None of these should be interpreted as a standalone longevity score.

Age, blood pressure, smoking, diabetes, family history and existing cardiovascular disease all affect the wider assessment of cardiovascular risk.

HbA1c gives a longer view of glucose exposure.

HbA1c reflects average blood glucose exposure over roughly the previous two to three months.

This makes it useful for understanding longer-term glycaemic status rather than relying on a single glucose measurement taken at one moment in time.

It is an important marker, but again it does not exist in isolation. Body composition, physical activity, diet, medication, family history and other health factors still matter.

IMULAB looks at HbA1c as part of the wider metabolic and cardiovascular picture rather than describing one result as a measure of longevity.

Kidney markers are part of the long-term picture.

Creatinine and estimated glomerular filtration rate, or eGFR, provide useful information about kidney filtration.

They need context. Creatinine can be influenced by factors including muscle mass, diet and hydration, which is particularly relevant when interpreting results in athletes.

Where kidney disease is being clinically assessed, blood measurements are not the entire assessment. Urinary albumin measurements can also be important.

A single slightly unusual result should therefore not be used to make assumptions about kidney health without considering the wider picture.

Liver markers need interpretation, not labels.

Liver panels commonly include markers such as ALT, AST, ALP, GGT, bilirubin and proteins produced by the liver.

Different markers tell us different things, and an abnormal result does not by itself identify a cause.

Recent strenuous exercise can also influence some enzymes, particularly AST, which is one reason training history matters when IMULAB interprets results in active people.

Trends, related biomarkers and clinical context matter more than treating one enzyme as a simple measure of liver health.

Full blood count and iron status still matter.

Longevity conversations often focus on newer or more unusual biomarkers, but basic blood health remains important.

A full blood count provides information about red cells, haemoglobin, white cells and platelets.

Iron status adds another layer, particularly when ferritin and the wider iron profile are considered alongside haemoglobin and red cell indices.

These measurements can be particularly relevant where someone has fatigue, reduced exercise tolerance, heavy menstrual losses or high endurance training demands.

More advanced does not always mean more useful. Established biomarkers still provide a considerable amount of information when interpreted properly.

Measure before building an unnecessary supplement stack.

This is where longevity can become unnecessarily complicated.

Large supplement stacks are often built around potential mechanisms rather than evidence that the individual actually needs the nutrient being supplemented.

Where a nutrient can be meaningfully assessed through blood testing, IMULAB prefers to establish status first.

Depending on the test, this may include vitamin D, vitamin B12, folate, iron-related markers and other nutritional measurements.

If an intervention is made, the relevant biomarker can then be retested to establish whether the intervention actually changed it.

Inflammatory markers are useful, but non-specific.

Markers such as CRP can indicate that an inflammatory response is present.

What they cannot do alone is tell us why.

Infection, injury, chronic inflammatory conditions and even recent strenuous exercise can influence inflammatory markers.

This makes context and repeat testing particularly important. One raised result should not be turned into a broad conclusion about long-term health without understanding what was happening at the time.

Hormones can be relevant. They are not a longevity score.

Testosterone, oestradiol, progesterone, SHBG, LH, FSH and other hormones may provide useful information in the right person and in the right context.

But higher is not automatically better.

Hormone concentrations vary with age, sex, menstrual cycle timing, sleep, energy availability, medication and other factors.

IMULAB therefore interprets hormone results as part of a wider physiological picture rather than treating a particular hormone level as evidence that someone is ageing well or badly.

The real value comes from knowing your own trend.

Population reference ranges are necessary, but they cannot tell us how an individual result has changed.

If a marker has been stable for several years and then begins moving consistently in one direction, that information may be useful even before it crosses a laboratory threshold.

This does not mean every small movement matters. Normal biological and laboratory variation exists.

It means repeated measurements taken under reasonably consistent conditions can add context that a single result cannot.

This is why IMULAB places so much emphasis on establishing a baseline rather than treating each blood test as an unrelated event.

You do not need to test constantly.

For someone establishing their blood data for the first time, IMULAB generally favours a broad baseline.

If that identifies something worth addressing, the relevant biomarkers can then be retested after an appropriate period.

There is often no reason to repeat the full panel every time.

Once the initial picture is understood and any areas of concern are stable, a broader assessment once or twice a year can provide useful longitudinal information.

More frequent testing may be appropriate where there is a specific reason, intervention or clinical requirement.